EV06
Phase 2- Indications
- Presbyopia
Company intelligence / Profile preview
Encore Vision Inc.
Fort Worth, Texas, United Statesencorevisionusa.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Encore Vision's lead product EV06 successfully passed FDA Phase 2 Clinical trials with no adverse reactions reported, while improving near point focus. The eye drops showed positive results in phase I/II clinical trials, demonstrating the ability to improve vision over three months[4][6].
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Encore Vision Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Encore Vision Inc..